Neovascular Glaucoma Associated with Chronic Rhegmatogenous Retinal Detachment

Neovascular Glaucoma ◽

Fundus Fluorescein Angiography ◽

Retinal Capillary ◽

Retinal Reattachment

Abstract Background To demonstrate the clinical features and natural course of chronic retinal detachment associated neovascular glaucoma. Methods Ten patients, diagnosed with chronic retinal detachment-associated neovascular glaucoma during 2007-2016 were retrospectively investigated. Besides chronic retinal detachment, no patients had any neovascular glaucoma-predisposing conditions, such as carotid artery disease. Retinal perfusion status was evaluated from postoperative visual acuity, intraocular pressures, ocular examination findings, and fluorescein angiography images. Results The mean age of patients was 57.5 (range: 22-78) years. Complete retinal reattachment was achieved in 3 eyes, while partial or total chronic retinal detachment persisted in 7 eyes. Wide-angle fundus fluorescein angiography revealed peripheral retinal capillary obstruction and severe non-perfusion. Neovascular glaucoma developed 213.4 months (17-634 months) after retinal detachment. Three eyes received Ahmed valve implantation, while 5 eyes received intravitreal bevacizumab injection. Intraocular pressure was controlled in 10 eyes. Two eyes developed phthisis bulbi during follow-up. Conclusions In eyes with a chronic retinal detachment history, iris neovascularization and neovascular glaucoma can develop due to retinal capillary obstruction and chronic retinal ischemia, even after achieving retinal reattachment. We suggest routine follow-up examinations for patients with chronic retinal detachment, particularly for eyes with retinal non-perfusion, as detected on fundus fluorescein angiography.

Role of bevacizumab intraocular injection in the management of neovascular glaucoma

International Journal of Ophthalmology ◽

10.18240/ijo.2021.06.10 ◽

2021 ◽

Vol 14 (6) ◽

pp. 855-859

Author(s):

Fawaz Al Sarireh ◽

◽

Khalid Al Zubi ◽

Khalil Al Salem ◽

◽

...

Keyword(s):

Intraocular Pressure ◽

Neovascular Glaucoma ◽

Retinal Ischemia ◽

Favorable Effect ◽

Complete Regression ◽

Long Term Effects ◽

Vein Occlusion

AIM: To assess the long-term effects of intraocular bevacizumab (Avastin) injections as an adjunctive drug to manage patients with neovascular glaucoma (NVG). METHODS: A retrospective study was conducted consisting of 34 eyes with secondary NVG caused by proliferative diabetic retinopathy (n=25), ischemic central retinal vein occlusion (n=8), and retinal ischemia resulting from persistent detachment (n=1) were managed by intraocular injections of bevacizumab (1.25 mg/0.05 mL), in addition to other treatments. The main outcome measure was the change in the degree of iris neovascularization. Secondary outcomes included intraocular pressure and the number of additional interventions or antiglaucoma medications administered after injection. RESULTS: All patients were followed-up for at least 12mo. At the last follow-up, complete regression of rubeosis irides was detectable in 13 (38.2%) eyes and incomplete regression in 21 eyes (61.8%). The mean intraocular pressure was 45.32±7.185 mm Hg at baseline and significantly decreased to 26.15±5.679 mm Hg at the last follow-up visit (P=0.000005). Patients received an average of 4.97 injections. As additional treatments, 12 eyes (35%) received laser photocoagulation and 6 eyes (18%) underwent retinocryopexy. No further treatment was needed in 16 eyes (47.1%). CONCLUSION: Intravitreal bevacizumab injection can have a favorable effect in controlling intraocular pressure and pain control in patients with NVG because it decreases the angiogenesis and helps to augment the results of conventional procedures. The primary cause of retinal ischemia should be always targeted.

Persistent exudative retinal detachment after photodynamic therapy and intravitreal bevacizumab injection for multiple retinal capillary hemangiomas in a patient with von Hippel–Lindau disease

Journal of the Chinese Medical Association ◽

10.1016/j.jcma.2013.09.001 ◽

2014 ◽

Vol 77 (1) ◽

pp. 52-56 ◽

Cited By ~ 11

Author(s):

Fang-Yi Tsai ◽

Ling-Ing Lau ◽

Shih-Jen Chen ◽

Fenq-Lih Lee ◽

Shui-Mei Lee

Keyword(s):

Photodynamic Therapy ◽

Retinal Detachment ◽

Exudative Retinal Detachment ◽

Von Hippel Lindau ◽

Retinal Capillary ◽

Von Hippel Lindau Disease ◽

Bevacizumab Injection

Massive Exudative Retinal Detachment Following Photodynamic Therapy and Intravitreal Bevacizumab Injection in Retinal Capillary Hemangioma

Korean Journal of Ophthalmology ◽

10.3341/kjo.2015.29.2.143 ◽

2015 ◽

Vol 29 (2) ◽

pp. 143 ◽

Cited By ~ 8

Author(s):

Hyeong Min Kim ◽

Kyu Hyung Park ◽

Se Joon Woo

Keyword(s):

Photodynamic Therapy ◽

Retinal Detachment ◽

Capillary Hemangioma ◽

Exudative Retinal Detachment ◽

Retinal Capillary ◽

Retinal Capillary Hemangioma ◽

Bevacizumab Injection

Pre-trabeculectomy intravitreal injections of Bevacizumab for treating neovascular glaucoma in diabetic patients

Vojnosanitetski pregled ◽

10.2298/vsp170531137m ◽

2020 ◽

Vol 77 (6) ◽

pp. 637-640

Author(s):

Ivan Marjanovic ◽

Marjan Marjanovic ◽

Ranko Gvozdenovic ◽

Marija Marjanovic ◽

Vujica Markovic ◽

...

Keyword(s):

Mitomycin C ◽

Neovascular Glaucoma ◽

Intravitreal Injections ◽

Adjunctive Treatment ◽

Diabetic Patients ◽

Open Label ◽

The Mean

Background/Aim. Neovascular glaucoma (NVG) is a secondary glaucoma caused by occlusion of the trabecular network of newly formed blood vessels. The aim of this study was to evaluate the efficacy and safety of intravitreal injections of bevacizumab before trabeculectomy with mitomycin C (MMC) for the treatment of NVG. Methods. A prospective and open-label study was conducted from May 2013 to December 2014 on consecutive NVG patients who underwent intravitreal injections of bevacizumab and a primary trabeculectomy with MMC. All patients were followed-up at least for 12 months. Success was defined as an intraocular pressure (IOP) of ? 21 mm Hg with or without topical ocular hypotensive medication. Results. Fourteen eyes of 12 diabetic patients fulfilled the respective demands of the inclusion and exclusion criteria. The mean (? standard deviation) follow-up period was 15.0 (? 2.0) months (range, 12 to 19 months). After one year of follow-up, 11 (78.6%) eyes had an IOP ? 21 mmHg. The mean IOP was significantly reduced from 42.4 (? 9.7) mmHg preoperatively to 18.4 (? 2.9) mmHg postoperatively (p < 0.0001). Regarding surgical complications, 6 months of trabeculectomy, hyphaema was observed in 3 (21.4%) eyes, macular edema in one (7.1%) eye and recurrence of neovascularization requiring intravitreal bevacizumab injection in 2 (14.2%) eyes. Conclusion. Preoperative intravitreal bevacizumab may be effective as adjunctive treatment for trabeculectomy with mitomycin-C for neovascular glaucoma patients.